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BACKGROUND: Genotype-guided initial warfarin dos-
ing may reduce over-anticoagulation and serious bleed-
ing compared to a one-dose-fits-all dosing method.
OBJECTIVE: The objective of this review was to inves-
tigate the safety and efficacy of genotype-guided dosing
of warfarin in reducing the occurrence of serious
bleeding events and over-anticoagulation.
DATA SOURCES: The authors searched PubMed,
EMBASE and International Pharmaceutical Abstracts
through January 23, 2009, without language restric-
tions. Selected articles were randomized trials compar-
ing pharmacogenetic dosing of warfarin versus a
“standard” dose control algorithm in adult patients
taking warfarin for the first time.
REVIEW METHODS: Two reviewers independently
extracted data and assessed study quality using a
validated instrument. The primary outcomes were
major bleeding and time spent within the therapeutic
range International Normalized Ratio (INR). Secondary
outcomes included minor bleeding, thrombotic events
and other measures of anticoagulation quality.
RESULTS: Three of 2,014 studies (423 patients) met
the inclusion and exclusion criteria. Differences in
study quality, dosing algorithms, length of follow-up
and outcome measures limited meta-analysis. Summa-
ry estimates revealed no statistically significant differ-
ence in bleeding rates or time within the therapeutic
range INR. The highest quality study found no signifi-
cant difference in primary or secondary outcomes,
although there was a trend towards more rapid achieve-
ment of a stable dose (14.1 vs. 19.6 days, p=0.07) in the
pharmocogenetic arm.
CONCLUSIONS: We did not find sufficient evidence to
support the use of pharmacogenetics to guide warfarin
therapy. Additional clinical trials are needed to define
the optimal approach to use warfarin pharmacogenetics
in clinical practice.
KEY WORDS: warfarin; pharmacogenetics; CYP2C9; VKORC1;
systematic review.
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BACKGROUND
In 2007 the Food and Drug Administration (FDA) issued a
labeling change advising physicians to consider the use of
“genetic tests to improve their initial estimate” of warfarin dose.
1
This is the first FDA recommendation to consider genetic testing
when initiating a commonly prescribed medication and may set
a precedent for the future use of genetic technologies in clinical
practice. Many forces are driving this technology into practice
with increasing numbers of companies promoting testing,
2–4
academic institutions racing to be on the cutting edge of clinical
medicine, and patients
5 interested in the potential of personal-
ized medicine. Indeed,warfarin has several attributes that make
it an attractive “target” of personalized medicine: it is commonly
prescribed,
6 has a narrow therapeutic index with up to 20-fold
inter-individual variability in dose-response,
7,8 an annual major
bleeding risk of 1–5%
9–13 and several common genetic variants
that affect warfarin metabolism and activity.
14–16
Warfarin dose variability is associated with many factors,
including age, height, body weight, race, dietary vitamin K
intake, intercurrent illness, drug interactions and genetic
variation.
17,18 Among Caucasians, an estimated 30% to 40%
of warfarin dose variability can be attributed to polymorphisms
in genes encoding hepatic isoenzyme cytochrome P-450 2C9
(CYP2C9), which is responsible for metabolic clearance of
warfarin, and vitamin K epoxide reductase complex subunit 1
(VKORC1), the enzymatic target of warfarin.
8,14,15,19–28
Allelic variants in CYP2C9 and VKORC1 are common, with
more than two thirds of the Caucasian population and up to
90% of East Asians manifesting at least one variant.
14–16
Affected individuals require, on average, lower doses of warfa-
rin to maintain a therapeutic INR and more time to achieve
stable dosing.
15,19,21,23,29–31 Carriers of variant alleles are at
higher risk for bleeding complications, particularly at the
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656induction of warfarin therapy,
32–37 and genotype-guided dos-
ing algorithms better approximate maintenance warfarin dose
than fixed-dose algorithms.
15,32,38–43 However, a recent anal-
ysis by Eckman and colleagues concluded that genotype-
guided dosing was unlikely to be cost-effective in nonvalvular
atrial fibrillation patients.
44 Furthermore, it remains unclear
whether pharmacogenetic dosing will reduce the incidence of
serious bleeding or over-anticoagulation compared to current
methods of initiating and dose-adjusting warfarin.
OBJECTIVES
In order to summarize the current evidence supporting the use
ofwarfarinpharmacogenetics,weperformedasystematicreview
of randomized trials that compared a dose-selection strategy
that used pharmacogenetic information to one that did not.
METHODS
Data Sources
We searched PubMed, EMBASE and the International Phar-
maceutical Abstracts through January 23, 2009. The complete
search strategy is described in the online Appendix 1. In order
to identify ongoing clinical trials, we searched http://www.
clinicaltrials.gov on February 19, 2009 (online Appendix 1). We
examined the reference lists of included articles and profes-
sional reviews, and contacted experts to identify other poten-
tially relevant studies.
We included randomized controlled trials that compared
clinical outcomes among a pharmacogenetic dosing group,
using common genetic variants of CYP2C9 and/or VKORC1,t o
a dosing algorithm that did not incorporate genetic testing.
Eligible studies enrolled adult, warfarin-naïve patients with
any indication for warfarin therapy, including atrial fibrillation,
venous thromboembolic disease, recent orthopedic surgery
and valvular disease.
Data Extraction
Two reviewers (KK, JT) independently extracted data using a
data abstraction instrument: number of participants in each
arm, study quality, length of follow-up period, intervention and
control dosing algorithms, and primary and secondary out-
comes. Our primary outcomes of interest were the incidence of
major bleeding events and time spent in therapeutic range
(INR between 2–3) as calculated by the linear interpolation
method,
45 an accepted measure of anticoagulation quality and
a potential surrogate for bleeding risk.
9,11 Our secondary out-
comes of interest included incidence of minor bleeding and
thromboembolism, and measures of over-anticoagulation and
inadequate anti-coagulation, including: time to first therapeutic
INR, time to stable warfarin dose, percentage time INR greater
than 3or4,andrelativenumberofINRblooddraws.We resolved
all disagreements by discussion and consensus. We contacted
the authors of the studies for additional information.
We used standard definitions for several outcomes. Major
bleeding was categorized according to an international con-
sensus statement
46 as any of the following: fatal bleeding,
symptomatic bleeding in a critical area or organ, a fall of
hemoglobin greater than or equal to 2 mg/dl, or requirement of
transfusion of two or more units of red cells or whole blood. For
one study,
47 we categorized gastrointestinal bleeds as major
bleeds because we were unable to ascertain the severity of
events reported. Percentage time in therapeutic range INR was
defined between 2 and 3 unless otherwise stated. Time to
stable warfarin dose was defined as two consecutive, thera-
peutic INR values separated by at least 7 days without
intervening dose alteration.
48
Studyqualitywasassessedusingthe Jadad scale.
49The score
ranged from 0 to 5 with higher scores indicating higher quality.
2
We further characterized study quality with assessment of:
allocation concealment, comparability of baseline groups, equiv-
alency of loss to follow-up, similarity of co-interventions and
whether the analysis was intention to treat.
Data Synthesis and Statistical Analysis
Quantitative data synthesis was performed using STATA
version 10 (STATA Corp, College Station, TX). Meta-analysis
was performed on primary outcomes. The principal measures
of effect size between the intervention and control arms were
risk ratio for major bleeding, and the standardized mean
difference (SMD) for percentage time INR within therapeutic
range (online Appendix 2). In one case,
48 we used a weighted
average of the percentage time within therapeutic range from
both the initiation (first 8 days) and stabilization period (day 9
through stable dose), because only separate estimates were
reported in the study. We used a random effects model
50 to
combine results across studies when appropriate and assessed
heterogeneity with the Q statistic
51 and I
2.
52–54 In order to test
for publication bias, we used the Begg adjusted rank correlation
test and the Egger regression asymmetry test.
55,56 Pre-specified
subgroups for sensitivity analyses included the quality of the
trials (poor versus good/excellent) and the length of follow-up
(< 30 days versus≥30). Sensitivity analysis by genes used in the
prediction model was not performed because there were too
few studies for it to be meaningful.
RESULTS
Study Characteristics
Our search identified 2,014 unique studies. Three studies
satisfied all inclusion and no exclusion criteria (Fig. 1). All
three studies were small, single-center randomized clinical
trials ranging from 38 to 238 patients (Table 1). Follow-up
ranged from 22 days in the pharmacogenetic arm of the study
by Caraco et al.
48 to an average of 46 days across both arms of
the study by Anderson et al.
57 Patients were almost exclusively
Caucasian (97%) older adults taking warfarin for the first time.
Demographic characteristics were similar between studies
(Table 2), but the treatment setting varied from predominantly
*
*The Jadad score rates randomized controlled trials on a 0–5 scale
where a higher score and gives one point for each of the following: (a) the
study was described as randomized, (b) the randomization technique
was described and appropriate, (c) the study was described as double-
blind, (d) the method of double-blinding was described and was
appropriate, and (e) withdrawals and reasons for withdrawals were
given.
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rin initiation were atrial fibrillation, atrial flutter, deep venous
thrombosis and pulmonary embolism in these three studies.
Hillman et al.
47 also included prosthetic valve and joint
patients, and Anderson et al.
57 included preoperative orthope-
dic patients. In all studies, observed genotype frequencies were
in accordance with Hardy-Weinberg equilibrium.
Each of the three studies used different dosing models for
their pharmacogenetic and control dosing arms, which is
reflected in the differing average initial doses across the three
studies in both groups (Table 1). For the pharmacogenetic arm,
the studies by Hillman et al.
47 and Caraco et al.
48 used dosing
models that accounted only for CYP2C9 variants, while
Anderson et al.
57 incorporated both CYP2C9 and VKORC1
variants. Two of the pharmacogenetic algorithms
47–57 were
previously validated and adjusted for covariates of age, sex and
weight. In contrast, Caraco et al.
48 created a new algorithm
that estimated warfarin dose based only on CYP2C9 genotype
and amiodarone use.
All three studies evaluated outcomes of bleeding and time
within therapeutic range. No study reported active surveillance
for clinical adverse events of bleeding or venous or arterial
thromboembolism.
Study Quality
Study quality varied substantially (Table 3). Caraco et al.
48
received the lowest Jadad score (1) for inadequate randomiza-
tion and blinding. Patients in this study were randomized by
the “even” or “odd” last digit of their identity number, and
investigators were not blinded after day 8 of follow-up. The
intention to treat principle was also violated: 51 excluded
patients had initiated warfarin therapy, but were not included
in the analyses, and there was no data comparing treatment
groups at randomization. The authors followed the control
arm, on average, for almost twice as long as the pharmacoge-
netic group (Table 1). However, time-dependent outcomes such
as number of bleeding events, percent time in therapeutic
range, time spent with out-of-range INR and total number of
INR draws were not adjusted to account for different lengths of
follow-up time.
The two remaining studies were of good quality overall.
Hillman et al.
47 received a Jadad score of 3 due to single-
blinded design. Anderson et al.
57 received the highest Jadad
score (5). However, despite adequate randomization in the
Anderson study,
57 there was a significantly higher percentage
of patients with ≥1 variant allele in CYP2C9 or VKORC1 among
the control group compared to the pharmacogenetics group
(p<0.01, Table 2).
Primary Outcomes
Primary outcomes of interest were rates of major bleeding and
percentage time INR in the therapeutic range (Table 4). None of
Figure 1. Flow diagram of process to select studies for inclusion:
search January 23, 2009. *General pharmacogenetic reviews,
warfarin drug interactions, other drugs metabolized by cytochrome
P450 enzymes. †Case report N=39, case control N=15, cohort
studies N=171. ‡References.
59,62,63
Table 1. Study Characteristics in the Randomized Trials of Genotype-Guided Warfarin Dosing
Author, year Study arm N Randomized N Losses Mean
follow-up,
days
Mean daily
starting
dose, mg
Gene(s)
tested
PG Algorithm C Algorithm
Hillman
47 PG 18 0 28 4.6 CYP2C9 Hillman model
70‡ Marshfield algorithm
71
2005 C 20 0 28 5
Caraco
48 PG 142 47 22 8.6 CYP2C9 Algorithm constructed
de novo
48
DAWN AC computer
algorithm
72 2007 C 141 45 40 6.7
Anderson
57 PG 101* N/R* 46 5.1† CYP2C9, VKORC1 Carlquist regression
equation
73‡
10 mg × 2 days,
then 5 mg
74 2007 C 99 N/R 46 5
PG: Pharmacogenetic arm; C: control dosing arm; N: number; N/R: not reported
*Data were not presented by study group. Of the patients, 206 were randomized; 6 dropped out: 3 because surgery was canceled, and 3 stopped warfarin
before the first INR was drawn
†Derived from weekly starting dose. Actual starting dose was double the algorithm PG: 10.2 mg, C: 10 mg × 2 days followed by regular dose per study by
Kovacs et al.
74
‡Multiple regression algorithms. In addition to genotype, Hillman et al.
47 accounted for age, sex, body surface area, concomitant medications, co-
morbidities and clinical indication; Anderson et al.
57 accounted for age, sex, weight
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major bleeding (Fig. 2), and the pooled risk ratio of 0.69 did not
achieve statistical significance (95% CI 0.16 to 2.9). While
there was no evidence of statistical heterogeneity (chi-squared
p=0.45, I
2=0.0%), there was clinically important variability in
the pharmacogenetic and control interventions, length of
follow-up and study quality. Egger’s regression did not show
evidence of publication bias (p=0.79); however, this estimate is
limited in the presence of only three studies (Online Appendix 3
shows estimates used for meta-analyses).
Figure 3 summarizes the differences in the percentage time
in therapeutic range across the three studies. No pooled
estimate is presented because there was significant heteroge-
neity (chi-squared p=0.03, I
2=72.5%). This outcome showed a
strong beneficial effect in the Caraco study,
48 but no effect in
the other two.
47,57 If the poor quality study is excluded, there is
no longer significant heterogeneity (chi-squared p=0.91, I
2=
0.0%), and the pooled estimate is not significant (p=0.76).
Notably, time within therapeutic range is as variable across the
three studies as it is between intervention groups in the
Caraco study
48 (Table 4). Other sources of heterogeneity
include differences in treatment algorithms and study quality,
differing frequency of INR measurements and differing lengths
of follow-up. Anderson et al.
57 used a more lenient definition of
therapeutic INR (1.8 to 3.2), which may also contribute to
heterogeneity. Sensitivity analysis using follow-up time of 30
days and a standard definition of therapeutic INR (2 to 3)
yielded a similar result (not shown). Heterogeneity remained
borderline significant (p=0.1, I
2=57.4%), suggesting that the
variability in study results was due to factors other than
differences in follow-up time or INR.
Secondary Outcomes
Overall, there were few consistent trends showing a difference
in secondary outcomes between the groups. Caraco et al.
48
reported an advantage for pharmacogenetic dosing compared
to the control group for several outcomes (Table 4), including
lower cumulative incidence of minor bleeding, decreased time
to first therapeutic INR, decreased time to stable warfarin
dose, decreased total number of INR draws and fewer days of
INR>3 (1.77 vs. 6.58, p<0.001). However, the longer follow-up
time in the control arm complicates the interpretation of time-
dependent results, including the number of bleeding events,
total number of INR draws and days of supratherapeutic INR.
It is noteworthy that the Hillman
47 and Anderson
57 studies did
not replicate these findings. No study showed a difference in
thromboembolism incidence.
The pharmacogenetic dosing groups showed improvement
in time to stable warfarin dose compared to the control groups
(Table 4) in two of the three studies
48,57 and was not reported
in the third.
47 Among the studies reporting this outcome, the
pharmacogenetic arm was favored with statistically significant
results by Caraco et al.
48 and near statistical significance by
Anderson and colleagues (14.1 versus 19.6 days, p=0.07).
57
The longer follow-up in the control arm of the Caraco
48 study
did not affect this result.
Ongoing Clinical Trials
We identified at least five ongoing randomized clinical trials
comparing pharmacogenetic dosing of warfarin therapy to a
non-genetic control algorithm (Table 5). Notably, the National
Table 2. Patient Characteristics in the Randomized Trials of Genotype-Guided Warfarin Dosing
Author, year Study arm Indication (%) Mean age, years Male sex, % % Patients with ≥1
variant allele
AF VTE Joint Valve Other
Hillman
47 PG 17 33 17 22 11 70.5 45 39
2005 C 45 15 15 20 5 68.8 44 35
Caraco
48 PG 37 63 0 0 0 57.6 46 37
2007 C 31 69 0 0 0 59.7 42 47
Anderson
57 PG 13 19 65 0 3 63.2 50 61*
2007 C 15 28 55 0 2 58.9 57 80
PG: Pharmacogenetic arm; C: control dosing arm; AF: atrial fibrillation, atrial flutter; VTE: venous thromoembolism; joint: prosthetic joint: valve: prosthetic
valve
*p<0.01. Higher relative percentage in both arms because Anderson et al.
57 evaluated variant alleles in both CYP2C9 and VKORC1
Table 3. Quality Assessment of the Randomized Trials of Genotype-Guided Warfarin Dosing
Author, year Quality * Randomization Allocation
conceal-ment
Comparable
groups at baseline
Patient
blinding
Co-interventions
equivalent
ITT Analysis
Hillman
47 3 Yes Yes Yes Yes Yes Yes
2005
Caraco
48 1 Pseudo No N/R No No No
2007
Anderson
57 5 Yes Yes No† Yes Yes Yes
2007
ITT: Intention to treat; N/R: not reported
*Jadad score
49 (0–2 poor, 3–4 good, 5 excellent)
† Higher number of variant alleles in the standard dosing arm (see Table 2); more hypertensive patients in the pharmacogenetic arm (p<0.02)
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(N=1,238), multi-center, double-blinded, randomized trial
comparing a recently validated
38,58 clinical plus genotype-
guided algorithm to a clinical only-guided dosing algorithm.
In all, randomized control experience of pharmacogenetic
dosing will encompass data collected from more than 2,500
patients.
DISCUSSION
Our study found little randomized trial data available to
support the hypothesis that pharmacogenetic dosing at the
onset of warfarin therapy reduces major bleeding events. An
extensive search yielded only three small randomized trials
evaluating pharmacogenetic dosing, and among these, there
was significant variability in terms of design quality, length of
follow-up, intervention and outcome measures. No study had
adequate power to evaluate differences in major bleeding rates
between groups. In the pooled estimates, there was a trend
towards less bleeding with pharmacogenetic dosing, but this
should be interpreted with caution because of the differences
in design between studies. Percentage time within therapeutic
range varied significantly across the studies even with stan-
dardized INR range and more uniform follow-up time. This
disparity raises concern that methods of ascertainment of this
outcome are likely to have differed between studies. There was
some evidence that time to stable warfarin dose may be
decreased with genotype-guided dosing.
The study by Anderson el al.
57 is the highest quality trial
published to date, and the only study that incorporated both
VKORC1 and CYP2C9. It is notable that there were more
variant alleles in the standard dosing arm compared to
pharmacogenetic arm of this study.
57 Because patients with
variant alleles are known to be more likely to have out of range
INR and bleeding complications, this difference could have
biased the results in favor of the pharmacogenetic arm.
Table 4. Primary and Secondary Outcomes in the Randomized Trials of Genotype-Guided Warfarin Dosing
Primary outcomes Secondary outcomes
Author,
year
Study
group
N Anal-yzed Major bleeds
N (%)
% Time INR
in range
Minor bleeds
N (%)
VTE N (%) Time to first
thera-peutic
INR, days
Time to stable
warfarin dose, days
Mean N
INR draws
Hillman
47 PG 18 2 (11)* 41.7 0 (0) 0 (0) N/R N/R N/R
2005 C 20 1 (5) 41.5 3 (15) 2 (10)
Caraco
48 PG 95 0 (0) 45.4† 3 (3.2)‡ 0 (0) 4.8§ 22.1§ 12.9§
2007 C 96 1 (1) 24.5 11 (11.4) 0 (0) 7.5 40.2 18.7
Anderson
57 PG 101 1 (1) 69.7 1 (1) 3 (3) 5.0 14.1║ 7.2
2007 C 99 3 (3) 68.6 2 (2) 1 (1) 6.1 19.6 8.1
PG: Pharmacogenetic arm; C: control dosing arm; N: number; VTE: venous thromboembolic events; N/R: not reported
*Gastrointestinal bleeding in paper; not clear if meet criteria for major bleed
†p<0.001. For the Caraco study,
48 the reported percentage of time INR in range is for the initiation phase (first 8 days). During the maintenance phase PG:
80.4% and C 63.4%, p<0.001
‡p=0.03
§p<0.001. For number of INR draws, Caraco et al.
48 reported number of INRs drawn from the stabilization phase (day 9 of the study period) to
maintenance (mean of day 22.1 in pharmacogenetic group and day 40.2 in control group). Daily INRs were drawn per protocol during the initiation phase
(day 1–8) in both groups; these eight draws are included in our analysis
║p=0.07
Figure 2. Forest plot. Meta-analysis of the risk ratio of major
bleeding between pharmacogenetic dosing and the control
group. This shows a pooled risk ratio of 0.69 favoring pharmaco-
genetics dosing, though it does not meet statistical significance
(95% CI 0.16 to 2.9).
Figure 3. Forest plot. Meta-analysis of average percentage time
spent in the therapeutic range. The SMD is the difference in time
spent in therapeutic range as a proportion of the standard
deviation around the average value for the entire group. Here, no
summary estimate is shown due to significant heterogeneity
(chi-squared p=0.03, I
2=72.5%).
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cogenetic dosing, but none achieved statistical significance.
Only the Caraco study
48 showed statistically significant
improvement in nearly all surrogate outcomes with pharma-
cogenetic dosing. However, the lack of true randomization and
allocation concealment, the high loss to follow-up, the lack of
intention to treat analysis and the different lengths of follow-up
between groups challenge the internal validity of these results.
Specifically, the outcomes of total number of bleeding events,
percentage time INR in therapeutic range, days of suprather-
apeutic INR and total number of INR draws are invalidated on
the basis of detection bias as a result of the nearly two-fold
increased follow-up time for the control group. As an example,
the total number of INR draws was 36% higher in the control
group, but the average interval between consecutive INR draws
was the same between groups.
Both the Hillman
47 and Anderson
57 studies used a multivar-
iable algorithm to select the initial dose for the patients in the
interventionarm,takingintoaccountnotonlythecontributionof
genetic variation, but also other well-established factors that are
knowntoaffectoverallwarfarindosesuchasage,sexandweight.
In contrast, patients in the control arms of these two studies
47,57
all received the same initial dose. Despite this seemingly unfair
advantage at the outset, neither of these studies demonstrated
statistically significant improvement of outcomes for the phar-
macogenetic arm.
Is pharmacogenetic dosing of warfarin more safe and
effective than a one-size-fits all strategy followed by careful
INR monitoring? The results of our study demonstrate that we
still do not know. An uncontrolled study
59 evaluating a
CYP2C9 dosing algorithm
40 in patients initiating warfarin
further highlights this uncertainty. Although the algorithm
estimated the maintenance warfarin dose well (R
2=0.42,
p<0.001), carriers of variant CYP2C9 alleles continued to have
a significantly increased risk of INR>4 (HR 4.6, p<0.01)
compared to those with the wild-type allele. There is evidence
that the greatest risk of warfarin-induced adverse events is at
the induction of warfarin therapy,
60 and that INR levels prior to
day 4 of therapy do not predict dose response differences.
Thus, the traditional “trial and error” method may result in
delays in estimating the appropriate dose.
41 However, Li and
colleagues
61 recently found that CYP2C9 and VKORC1 geno-
types did not add to early INR response as a predictor of
warfarin sensitivity. Even if pharmacogenetic dosing does not
reduce major bleeding, it may still be useful and cost effective if
it results in shorter time to stable dose, and fewer blood draws
to attain stable INR. It is possible, however, that physicians
may become more complacent with pharmacogenetic dosing
resulting in reduced surveillance and a paradoxical increase in
bleeding during the initiation of warfarin therapy.
Our study has limitations. First, very little high-quality
evidence has been published in this area: we identified only
three small randomized trials evaluating pharmacogenetic
dosing of warfarin. Second, important differences in designs,
outcome definitions and follow-up intervals used by these
three trials reduced the degree to which we could pool their
individual findings. We did not perform meta-analysis of
secondary outcomes because of significant heterogeneity of
the trials. Third, we did not evaluate genotype-specific out-
comes, because these are not relevant when providers are
unaware of genotypes in advance. Lastly, we did not include
the three prospective cohort studies using genotype-guided
algorithms,
59,62,63 because others have reviewed this litera-
ture,
64,65 and we decided a priori that only randomized trials
could reliably demonstrate whether pharmacogenetic dosing
improves patient outcomes. It may be considered early to
perform a systematic review on a topic where so few random-
ized controlled trials are available; however, given the FDA
relabeling, we feel it is important to evaluate the current
evidence.
The package insert of warfarin advises that “lower initiation
doses should be considered for patients with certain genetic
Table 5. Ongoing Randomized Trials Comparing Pharmacogenetic Warfarin Dosing to a Control-Dosing Algorithm Among Patients Starting
Warfarin Therapy
PI Title/clinical trials identifier Country/sponsor N Outcome Expected
completion
Caldwell Modeling genotype and other factors to enhance
the safety of coumadin prescribing/NCT00484640
US/AHRQ 260 1°: PTTR, deviation from
optimal dose
NR*
2°: time to stable dose,
time to INR>4,
adverse events
Caraco Genetic determinants of warfarin anticoagulation
effect/NCT00162435
Israel/Hadassah
Medical Organization
500 Time to therapeutic INR,
PTTR, bleeding events
NR
Destache Comparison of warfarin dosing using decision model
versus pharmacogenetic algorithm/NCT00511173
US/Creighton University 250 Clinical outcomes, NOS 6/2009
Kimmel Clarification of optimal anticoagulation through
genetics (COAG) /NCT00839657
US - Multi-center/NHLBI 1238 1°: PTTR 3/2012
2°: time to stable dose
McMillin Prospective genotyping for total hip or knee replacement
patients receiving warfarin (coumadin)/NCT00634907
US/University of Utah 263 1°: Adverse events Completed
8/2008 2°: Improved anticoagulation
management
AHRQ: Agency for Healthcare Research and Quality
NHLBI: National Heart, Lung, and Blood Institute
NR: Not reported
NOS: Not otherwise specified
PTTR: Percentage of time participants spend within the therapeutic INR range
PI: Principal investigator
*Estimated study completion date reported May 2008, but per clinicaltrials.gov this study is not yet open for participant recruitment
661 Kangelaris et al.: Systematic Review of Pharmacogenetic Warfarin Dosing JGIMvariations in CYP2C9 and VKORC1 enzymes.” This FDA
labeling change was made on the basis of accumulation of
data
66 demonstrating that allelic variants in CYP2C9 and
VKORC1 are associated with increased plasma warfarin levels,
out of range INR and increased bleeding risk.
15,19,23,35,67,68
However, as our study demonstrates, there is no evidence that
a more accurate initiation dose reduces the risk of bleeding.
Results from ongoing clinical trials will help to clarify the role
of genetic testing in warfarin management. A target enrollment
of at least 2,000 patients has been suggested,
57 and currently
the cumulative experience of >2,500 patients is anticipated.
Each of the randomized trials reviewed in our study used
different pharmacogenetic and control group dosing algo-
rithms. The most comprehensive and widely available phar-
macogenomic algorithm, http://www.WarfarinDosing.org, has
been recently validated by the The International Warfarin
Pharmacogenetics Consortium and will be used in the largest
randomized trial sponsored by the NHLBI.
38 Until recently,
however, there was no widely accepted pharmacogenetic
algorithm to guide the initiation of warfarin therapy, and new
models are still being developed and validated.
69 Although
warfarin dosing algorithms do not eliminate the need for
frequent INR monitoring and dose titration, these algorithms
can, even in the absence of genotype information, provide a
very good estimate of the patient’s warfarin dose by taking into
account readily available information such as age, gender,
weight and smoking status.
38 Whether these algorithms
improve outcomes compared to other warfarin initiation
strategies is not known.
The products of genetic discovery are becoming increasingly
relevant to the practice of clinical medicine, particularly in the
realm of pharmacogenetics. Genotype-guided warfarin pre-
scribing is currently the focus of much attention and is
positioned to set a precedent for how integration of genetic
technologies in clinical practice will proceed. In the case of
warfarin, it seems intuitive that adjusting warfarin dose to
match patients’ genetic makeup will result in fewer complica-
tions; however, our review, along with at least one unfavorable
cost-effectiveness analysis,
44 demonstrates that additional
clinical trial data are needed prior to endorsing a new standard
of care for warfarin dosing.
CONCLUSION
In conclusion, our study did not find sufficient evidence to
support the use of pharmacogenetics to guide warfarin therapy
outside of clinical trials at this time. Small sample sizes and
heterogeneity across the few available studies precluded
definitive estimates of the relative effectiveness of this inter-
vention. We recommend that policy makers and clinicians
await the results of larger, high quality randomized trials and
better cost-effectiveness analyses before adopting genetic
testing as the standard of care for warfarin initiation.
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